학술논문

Abstract 1122‐000150: Novel Ischemic Stroke Treatment Protocol for Salvageable Penumbra in Acute Small Vessel Disease
Document Type
article
Source
Stroke: Vascular and Interventional Neurology, Vol 1, Iss S1 (2021)
Subject
Treatment
Penumbra
Cerebrovascular Disease
Basic/Translational Vascular Science
Antiplatelet
Neurology. Diseases of the nervous system
RC346-429
Diseases of the circulatory (Cardiovascular) system
RC666-701
Language
English
ISSN
2694-5746
Abstract
Introduction: In small vessel disease (SVD)‐related acute ischemic stroke (AIS), no specific acute treatment exists. We propose an acute treatment protocol for patients with fluctuating exam secondary to salvageable micropenumbra in high risk SVD‐related AIS. Methods: Inclusion criteria included acute SVD‐related stroke with NIHSS fluctuation ≥ 2 previously described as a sensitive indicator of neurological deterioration in SVD ischemic stroke. Patients with large vessel atheroma secondarily causing stroke were excluded. Treatment protocol consisted of albumin IV, eptifibatide IV, magnesium sulfate IV, cilostazol PO, normoglycemia, normothermia, aggressive fluid resuscitation, and targeted blood pressure parameters in a neurocritical care setting. Protocol was prospectively initiated in August 2020 at onset of exam fluctuation and continued until plateau NIHSS was reached. Retrospective data for subjects from January 2017 to July 2020 was collected for historical controls. Primary outcomes measures included safety and early efficacy end points. Efficacy was measured by change from maximum NIHSS to plateau NIHSS (NIHSS‐diff). Wilcoxon rank‐sum test was used to evaluate significant difference of NIHSS‐diff in both groups. Social Science Statistics was used for data analysis. Results: From January 2017 ‐ May 2021, out of 7,146 AIS patients, 30 met selection criteria. From August 2020 to May 2021, consecutive subjects received treatment protocol (n = 15, baseline NIHSS 4.93, 95% CI [3.3572, 6.5028]). They were compared with historical controls (n = 15, baseline NIHSS 5.87, 95% CI [2.9407, 8.7993]). There was no significant difference in baseline characteristics (p = 1; U = 112 at p